Eris Lifesciences Limited (BOM:540596)
1,319.50
-8.40 (-0.63%)
At close: Nov 20, 2026
Eris Lifesciences Revenue
Eris Lifesciences had revenue of 8.90B INR in the quarter ending September 30, 2026, with 12.57% growth. This brings the company's total for the last twelve months to 33.12B, up 10.89% year-over-year. In the fiscal year ending March 31, 2026, Eris Lifesciences had annual revenue of 31.15B with 8.18% growth.
Revenue (ttm)
33.12B
Revenue Growth
+10.89%
P/S Ratio
5.52
Revenue / Employee
12.01M
Employees
2,758
Market Cap
182.75B
Revenue by Geography
- India 27.73B 89.0%
- outside India 3.42B 11.0%
Fiscal year ended Mar 31, 2026 See the full Eris Lifesciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 31.15B | 2.36B | 8.18% |
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 97.79B |
| Alembic Pharmaceuticals | 84.77B |
| Strides Pharma Science | 52.13B |
| Akums Drugs and Pharmaceuticals | 48.29B |
| Wockhardt | 38.40B |
| Eris Lifesciences | 33.12B |
| NATCO Pharma | 30.92B |
| Alivus Life Sciences | 26.84B |
Eris Lifesciences News
- 27 days ago - Eris Lifesciences Transcript: Q2 26/27 - Transcripts
- 27 days ago - Eris Lifesciences Quarterly report: Q2 2027 - Filings
- 27 days ago - Eris Lifesciences Slides: Q2 2027 - Filings
- 3 months ago - Eris Lifesciences Transcript: Q1 26/27 - Transcripts
- 3 months ago - Eris Lifesciences Slides: Q1 2027 - Filings
- 3 months ago - Eris Lifesciences Quarterly report: Q1 2027 - Filings
- 5 months ago - Eris Lifesciences Slides: Corporate presentation - Filings
- 5 months ago - Eris Lifesciences achieves top-5 market position in anti-diabetes therapy - Business Upturn